USD 3.09
(6.19%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 5.18 Million USD | 106.51% |
2022 | 2.5 Million USD | 55.04% |
2021 | 1.61 Million USD | 6929.0% |
2020 | 23.02 Thousand USD | 0.0% |
2019 | - USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 2.55 Million USD | 47.01% |
2024 Q1 | 1.73 Million USD | 3.55% |
2023 FY | 5.18 Million USD | 106.51% |
2023 Q3 | 1.56 Million USD | 38.14% |
2023 Q2 | 1.13 Million USD | 39.6% |
2023 Q4 | 1.67 Million USD | 7.24% |
2023 Q1 | 810.4 Thousand USD | 1.76% |
2022 FY | 2.5 Million USD | 55.04% |
2022 Q2 | 461.79 Thousand USD | 10.38% |
2022 Q1 | 418.38 Thousand USD | 16.03% |
2022 Q3 | 832.1 Thousand USD | 80.19% |
2022 Q4 | 796.37 Thousand USD | -4.29% |
2021 Q3 | 930.44 Thousand USD | 293.2% |
2021 FY | 1.61 Million USD | 6929.0% |
2021 Q1 | 90.42 Thousand USD | 292.79% |
2021 Q2 | 236.63 Thousand USD | 161.7% |
2021 Q4 | 360.57 Thousand USD | -61.25% |
2020 Q3 | - USD | 0.0% |
2020 Q2 | - USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2020 FY | 23.02 Thousand USD | 0.0% |
2020 Q4 | 23.02 Thousand USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 FY | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Esperion Therapeutics, Inc. | 116.33 Million USD | 95.547% |
Theratechnologies Inc. | 81.76 Million USD | 93.664% |
Safety Shot Inc | 202.67 Thousand USD | -2456.19% |
Cosmos Health Inc. | 53.37 Million USD | 90.294% |
Cronos Group Inc. | 88.84 Million USD | 94.169% |
Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 98.83% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Organogenesis Holdings Inc. | 433.14 Million USD | 98.804% |
Universe Pharmaceuticals INC | 32.3 Million USD | 83.965% |
ProPhase Labs, Inc. | 44.38 Million USD | 88.328% |
Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 59.32% |
Dynavax Technologies Corporation | 232.28 Million USD | 97.77% |
Radius Health, Inc. | 2.88 Billion USD | 99.82% |
China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -168.636% |
Alvotech | 91.43 Million USD | 94.334% |
Sunshine Biopharma, Inc. | 24.09 Million USD | 78.497% |
Alpha Teknova, Inc. | 36.68 Million USD | 85.878% |
Intra-Cellular Therapies, Inc. | 464.37 Million USD | 98.884% |
SCYNEXIS, Inc. | 140.14 Million USD | 96.303% |
Harrow Health, Inc. | 130.19 Million USD | 96.021% |
Biofrontera Inc. | 34.07 Million USD | 84.795% |
DURECT Corporation | 8.54 Million USD | 39.394% |
Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 99.147% |
ANI Pharmaceuticals, Inc. | 486.81 Million USD | 98.936% |
OptiNose, Inc. | 70.98 Million USD | 92.702% |
RedHill Biopharma Ltd. | 6.51 Million USD | 20.459% |
Aquestive Therapeutics, Inc. | 50.58 Million USD | 89.758% |
Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 86.902% |
SIGA Technologies, Inc. | 139.91 Million USD | 96.297% |
Lifecore Biomedical, Inc. | 128.26 Million USD | 95.961% |
Shineco, Inc. | 9.8 Million USD | 47.146% |
Phibro Animal Health Corporation | 1.01 Billion USD | 99.491% |
Procaps Group S.A. | 409.92 Million USD | 98.736% |
TherapeuticsMD, Inc. | 1.3 Million USD | -297.898% |
Regencell Bioscience Holdings Limited | - USD | -Infinity% |
Viatris Inc. | 15.42 Billion USD | 99.966% |
Sunshine Biopharma, Inc. | 24.09 Million USD | 78.497% |
Rockwell Medical, Inc. | 83.61 Million USD | 93.804% |
Incannex Healthcare Limited | 12 Thousand USD | -43071.917% |
Aytu BioPharma, Inc. | 81 Million USD | 93.604% |
Tilray Brands, Inc. | 788.94 Million USD | 99.343% |
Collegium Pharmaceutical, Inc. | 566.76 Million USD | 99.086% |
PetIQ, Inc. | 1.1 Billion USD | 99.53% |
Silver Spike Investment Corp. | 11.72 Million USD | 55.805% |
Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.725% |
Journey Medical Corporation | 79.18 Million USD | 93.457% |
Alimera Sciences, Inc. | 80.75 Million USD | 93.585% |
Petros Pharmaceuticals, Inc. | 5.82 Million USD | 11.022% |
Assertio Holdings, Inc. | 152.06 Million USD | 96.593% |
Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Embecta Corp. | 1.12 Billion USD | 99.538% |
Cyclo Therapeutics, Inc. | 1.07 Million USD | -381.29% |
Procaps Group, S.A. | 409.92 Million USD | 98.736% |
PainReform Ltd. | - USD | -Infinity% |
Avadel Pharmaceuticals plc | 27.96 Million USD | 81.473% |
Hempacco Co., Inc. | 4.04 Million USD | -28.055% |
Talphera, Inc. | 651 Thousand USD | -695.796% |
Pacira BioSciences, Inc. | 674.97 Million USD | 99.232% |
Alvotech | 91.43 Million USD | 94.334% |
Lantheus Holdings, Inc. | 1.29 Billion USD | 99.6% |
Kamada Ltd. | 144.75 Million USD | 96.421% |
Indivior PLC | 1.09 Billion USD | 99.526% |
Currenc Group, Inc. | 53.25 Million USD | 90.272% |
Flora Growth Corp. | 76.07 Million USD | 93.19% |
Cyclo Therapeutics, Inc. | 1.07 Million USD | -381.29% |
Evolus, Inc. | 202.08 Million USD | 97.436% |
HUTCHMED (China) Limited | 837.99 Million USD | 99.382% |
Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 99.196% |
Akanda Corp. | 2.16 Million USD | -139.838% |